RBD-7022 is under clinical development by Suzhou Ribo Life Sciences and currently in Phase I for Hyperlipidemia.

Alarming trends in the rates of premature coronary heart disease among younger women in wealthy nations prompted a group of U.S. researchers to try to pinpoint their risk factors for CHD ...